Sec Form 4 Filing - DSM International B.V. @ AMYRIS, INC. - 2017-08-07

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person DSM International B.V. 2. Issuer Name and Ticker or Trading Symbol AMYRIS, INC. [ AMRS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) HET OVERLOON 1 3. Date of Earliest Transaction (MM/DD/YY) 08/07/2017 (Street) HEERLEN, P76411 TE 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/08/2017 J( 1 ) 7,936,232 A 7,936,232 I See footnote ( 3 ) Common Stock 08/08/2017 X 748,728 A $ 0.0015 8,684,960 I See footnote ( 3 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series B Preferred Stock ( 2 ) 08/07/2017 P 25,000 ( 2 ) ( 2 ) Common Stock 3,968,116 ( 2 ) 50,000 I See footnote ( 3 ) Warrants (right to buy) $ 6.3 08/07/2017 P 3,968,116 08/07/2017 08/07/2022 Common Stock 3,968,116 $ 0 0 I See footnote ( 3 ) Series B Preferred Stock ( 2 ) 08/08/2017 J( 1 ) 50,000 ( 2 ) ( 2 ) Common Stock 7,936,232 ( 2 ) 0 I See footnote ( 3 ) Warrants (right to buy) $ 0.0015 08/08/2017 J( 4 ) 748,728 08/08/2017 07/07/2022 Common Stock 748,728 $ 0 748,728 I See footnote ( 3 ) Warrants (right to buy) $ 0.0015 08/08/2017 X 748,728 08/08/2017 07/07/2022 Common Stock 748,728 $ 0 0 I See footnote ( 3 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other DSM International B.V. HET OVERLOON 1 HEERLEN, P76411 TE X Koninklijke DSM N.V. HET OVERLOON 1 HEERLEN, P76411 TE X Signatures DSM International B.V. /s/ Hugh Welsh, President, DSM North America 08/09/2017 Signature of Reporting Person Date Koninklijke DSM N.V. /s/ Hugh Welsh, President, DSM North America 08/09/2017 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On August 8, 2017, the reporting person converted 50,000 shares of Series B Preferred Stock, resulting in the issuance of 7,936,232 shares of Common Stock. ( 2 )Each share of Series B Preferred Stock is convertible at any time at the option of the holder into approximately 158.7 shares of Common Stock, subject to certain adjustments. The Series B Preferred Stock has no expiration date. ( 3 )The securities reported herein are held of record by DSM International B.V., which is a wholly owned subsidiary of Koninklijke DSM N.V. Accordingly, Koninklijke DSM N.V. may be deemed to share beneficial ownership of the securities held of record by DSM International B.V. Koninklijke DSM N.V. is a publicly traded company with securities listed on the Amsterdam Stock Exchange. ( 4 )In connection with an investment in the Issuer by a third party, the anti-dilution provisions of the Warrants were triggered, resulting in the Warrants becoming exercisable for 748,728 shares of Common Stock at an exercise price of $0.0015 per share upon exercise by the reporting person on August 8, 2017.

Remarks: ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations.See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.